Dr Paul Frohna Discusses Promising Results of Novel Hedgehog Inhibitor for IPF
Promising results from a phase 2 trial of ENV-101, a novel hedgehog inhibitor, showed improvement in lung function and reduction of fibrosis in patients with idiopathic pulmonary fibrosis, said Paul Frohna, MD, PhD, PharmD.
United States San Diego Paul Frohna American Thoracic Society International Conference Endeavor Biomedicines
Source: ajmc.com